TransEnterix Inc., has announced the pricing of its underwritten public offering of 16,666,667 Common shares at a price of $3.00 per share for total gross proceeds of $50.0 Million. The firm plans to use the net proceeds from this offering for research and development, sales, marketing, and commercialization of coming products. View the full release here.
News: TransEnterix Offer Pricing $TRXC Read More »
Chimerix Inc., has priced its public offering of 3.775 Million Common shares at $39.75 per share. Gross Proceeds would be of $150,056,250. Bid will be closed by June 16, and the Net proceeds will fund R&D, working capital and general corporate purposes. View the full release here.
News: Chimerix Equity Offering $CMRX Read More »
BIND Therapeutics, Inc., a clinical-stage nanomedicine company, has teamed up with Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, Inc. The Collaboration has came to engineer Accurins for efficient binding to CD206 positive disease-associated macro phages. View the full release here.
News: BIND, Navidea teams against Cancer $BIND Read More »
Cellectis Inc., has publishing for the first time its 1st quarter results in order to comply with NASDAQ. Earlier the firm has released results which shows Total Revenues of €9.2 Million and EPS was reported €0.23. View the full earnings release here.
Earnings: Cellectics Published Quarterly Results $CLLS Read More »
Synergetics USA, Inc., a medical device company, has announced its thiord quarter results for FY-2014-15. The results shows EPS rise to $0.05 from $0.04 YoY, while Total Sales up by 20.1% to $19.4 million YoY. View the full earnings release here.
Earnings: Synergetics Earnings Up $SURG Read More »
